Research programme: small-molecule oral therapeutics - Principia Biopharma

Drug Profile

Research programme: small-molecule oral therapeutics - Principia Biopharma

Alternative Names: PRN 2246

Latest Information Update: 28 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Principia Biopharma
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Interleukin 17 receptor antagonists; Interleukin-17 inhibitors; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; CNS disorders; Inflammation
  • Discontinued Haematological malignancies

Most Recent Events

  • 18 Oct 2017 Principia Biopharma plans a phase I trial for Multiple sclerosis (In Volunteers) in Australia in April 2018 (ACTRN12617001457336)
  • 27 Jan 2017 Discontinued - Preclinical for Haematological malignancies in USA (PO)
  • 27 Jan 2017 Preclinical trials in Autoimmune disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top